Want to see FR:ALCLS full AI Analyst Report?
Top Page
Cellectis SA
(ALCLS)
Select Model
Select Model
Rating:41Neutral
Price Target:
€1.50
▼(-51.61% Downside)
Action:Upgraded
Date:09/15/26
The score is driven primarily by weak financial performance (declining TTM revenue, deep losses, higher leverage, and significant cash burn suggesting ongoing funding risk). Technicals further weigh on the outlook with the stock far below major moving averages and weak momentum. Valuation is not a mitigating factor given negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Gene-edited cell therapy platform
Cellectis is developing an allogeneic, off-the-shelf cell therapy platform supported by gene-editing and cell-engineering capabilities. If clinical programs advance, this approach could enable more standardized products and create collaboration, licensing, milestone, and royalty opportunities.
Negative Factors
Declining revenue
The recent revenue contraction and volatile multi-year trajectory make it difficult to establish a dependable growth base. For a clinical-stage company reliant on collaborations, inconsistent partner payments can reduce visibility into funding capacity and delay the point at which the platform can support sustained operating scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Gene-edited cell therapy platform
Cellectis is developing an allogeneic, off-the-shelf cell therapy platform supported by gene-editing and cell-engineering capabilities. If clinical programs advance, this approach could enable more standardized products and create collaboration, licensing, milestone, and royalty opportunities.
Read all positive factors
Cellectis SA (ALCLS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€190.51M
Dividend YieldN/A
Average Volume (3M)128.66K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth-5.98%
EPS Growth-8.67%
CountryFR
Employees227
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.65
Shares Outstanding72,325,455
10 Day Avg. Volume120,055
30 Day Avg. Volume128,656
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.71
Revenue Forecast (FY)€45.70M
Cellectis SA Business Overview & Revenue Model
Company Description
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chime...
How the Company Makes Money
Cellectis makes money primarily through (1) collaboration and licensing arrangements and (2) other partner-related payments tied to its technology and product-candidate pipeline, rather than through product sales (as it is clinical-stage). Revenue...
Cellectis SA Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.Positive Updates
Initiation of Pivotal Phase II Trial for lasme-cel
Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Negative Updates
Servier Arbitration
Cellectis is engaged in arbitration with Servier regarding the termination of a licensing agreement, seeking compensation for losses due to lack of development of licensed products. The decision is expected by December 15, 2025.
Read all updates
Q2-2025 Updates
Positive
Negative
Initiation of Pivotal Phase II Trial for lasme-cel
Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Read all positive updates
Company Guidance
During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.Cellectis SA Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.58M | 75.92M | 41.51M | 755.00K | 19.17M | 73.95M |
| Gross Profit | 42.25M | 55.04M | 41.51M | 18.00K | 17.40M | 37.67M |
| EBITDA | -43.63M | -21.12M | -9.46M | -92.64M | -76.38M | -85.44M |
| Net Income | -65.27M | -70.35M | -36.76M | -101.06M | -98.69M | -86.28M |
Balance Sheet | ||||||
| Total Assets | 267.37M | 324.72M | 383.54M | 334.27M | 261.22M | 382.08M |
| Cash, Cash Equivalents and Short-Term Investments | 166.85M | 208.66M | 260.31M | 203.81M | 97.70M | 186.13M |
| Total Debt | 84.57M | 90.73M | 91.46M | 85.06M | 82.85M | 102.24M |
| Total Liabilities | 226.30M | 248.85M | 252.51M | 249.57M | 135.28M | 145.60M |
| Stockholders Equity | 41.07M | 75.91M | 131.03M | 84.69M | 117.97M | 221.29M |
Cash Flow | ||||||
| Free Cash Flow | -43.86M | -44.10M | 19.15M | -25.82M | -89.89M | -124.31M |
| Operating Cash Flow | -41.69M | -41.64M | 22.99M | -24.75M | -87.44M | -104.56M |
| Investing Cash Flow | 33.13M | -30.69M | -102.81M | -15.51M | -2.76M | 7.28M |
| Financing Cash Flow | -16.31M | -16.81M | 89.11M | 82.86M | 1.15M | 47.52M |
Cellectis SA Technical Analysis
Negative
3.10
Price Trends
2.66
Negative
2.82
Negative
3.16
Negative
Market Momentum
0.02
Positive
43.43
Neutral
8.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 3.1 is above the 20-day moving average (MA) of 2.85, above the 50-day MA of 2.66, and below the 200-day MA of 3.16, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 43.43 is Neutral, neither overbought nor oversold. The STOCH value of 8.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.
Cellectis SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €177.38M | -2.85 | 593.93% | ― | -77.92% | 11.11% | |
47 Neutral | €245.16M | -3.38 | -63.53% | ― | 291.43% | 12.24% | |
46 Neutral | €1.58B | -61.02 | 31.23% | ― | ― | ― | |
46 Neutral | €51.57M | -1.29 | ― | ― | 40.67% | 11.49% | |
43 Neutral | €63.71M | -1.61 | -96.73% | ― | -96.25% | -197.89% | |
41 Neutral | €190.51M | -2.66 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
FR:ALCLS
Cellectis SA
1.51
-1.17
-43.63%
FR:IPH
Innate Pharma SA
1.57
-0.25
-13.75%
FR:NANO
Nanobiotix
31.12
23.17
291.45%
FR:TNG
Transgene
0.88
-0.28
-23.98%
FR:OSE
OSE Immunotherapeutics SA
2.71
-3.24
-54.39%
FR:MAAT
MaaT Pharma
2.52
-1.60
-38.81%
Cellectis SA Corporate Events
Cellectis pivots to in vivo gene editing and exits key CAR-T programs
Sep 14, 2026
Cellectis has approved a strategic shift to focus on in vivo gene editing, advancing two lead programs, .HEAL-101 and .HEAL-201, targeting severe hypertriglyceridemia and hypercholesterolemia with first Phase 1 data expected in China in 2027 and 2...
Cellectis Plans September 14 Business Update Webcast for Global Investors
Sep 11, 2026
Cellectis SA will host an English- and French-language conference call and webcast on September 14, 2026 to provide a business update to investors and other stakeholders. The company plans to make a replay available on its website, underscoring it...
Cellectis Updates Share Capital and Voting Rights as of August 31, 2026
Sep 3, 2026
Cellectis SA reported that as of August 31, 2026, its share capital consisted of 100,718,974 shares, corresponding to 105,568,956 voting rights. The update on capital and voting rights provides investors and market participants with greater transp...
Cellectis Advances Allogeneic CAR-T Pipeline as Cash Runway Extends Into Late 2027
Aug 6, 2026
Cellectis reported progress across its allogeneic CAR-T pipeline, highlighting lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia and eti-cel for relapsed or refractory non-Hodgkin lymphoma, alongside a cash runway into the f...
Cellectis Updates Share Capital and Voting Rights as of July 31, 2026
Aug 5, 2026
Cellectis SA reported that its share capital comprised 100,701,207 shares as of July 31, 2026, corresponding to 105,554,794 voting rights. The updated figures clarify the company’s current capital and governance structure for shareholders an...
Cellectis Sets August 6 Date to Release Q2 2026 Results
Jul 30, 2026
Cellectis announced it will release its financial results for the second quarter of 2026, covering the period ended June 30, after the close of the U.S. market on August 6. The results will be disseminated via a press release posted in the investo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.